Cargando…
Identification of cisplatin-binding sites on the large cytoplasmic loop of the Na(+)/K(+)-ATPase
Cisplatin is the most widely used chemotherapeutic drug for the treatment of various types of cancer; however, its administration brings also numerous side effects. It was demonstrated that cisplatin can inhibit the Na(+)/K(+)-ATPase (NKA), which can explain a large part of the adverse effects. In t...
Autores principales: | Šeflová, Jaroslava, Čechová, Petra, Štenclová, Tereza, Šebela, Marek, Kubala, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6009960/ https://www.ncbi.nlm.nih.gov/pubmed/29577756 http://dx.doi.org/10.1080/14756366.2018.1445735 |
Ejemplares similares
-
Flavonolignans As a Novel Class of Sodium Pump Inhibitors
por: Kubala, Martin, et al.
Publicado: (2016) -
Identification of the retinoschisin-binding site on the retinal Na/K-ATPase
por: Plössl, Karolina, et al.
Publicado: (2019) -
Access of Extracellular Cations to their Binding Sites in Na,K-ATPase: Role of the Second Extracellular Loop of the α Subunit
por: Capendeguy, Oihana, et al.
Publicado: (2006) -
Procyanidin C1 from Viola odorata L. inhibits Na(+),K(+)-ATPase
por: Heger, Tomas, et al.
Publicado: (2022) -
Cyclosporine A inhibits MRTF‐SRF signaling through Na(+)/K(+) ATPase inhibition and actin remodeling
por: Burat, Bastien, et al.
Publicado: (2019)